TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search

DSNKY

Daiichi Sankyo Co Ltd ADR

PINKCommon Stock
$16.42
+1.42%today

No SEC filings for this security

Daiichi Sankyo Co Ltd ADR is a foreign or OTC-listed security (PINK) that doesn't file with the SEC, so the grounded research view — financials, filings, insider activity and the call — isn't available. Price and news only.

Key stats

52-week range$15.10 – $26.91
15.1052-week26.91
Market cap
$29.9B
Volume
37.0K
1Y return
-26.06%
Beta
-0.15

Price · 1Y

$16.42▼ -26.06%
over 1Y
L $15.10H $26.91

Recent news

market news →
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)Bullish
finance.yahoo.com· 2026-07-01
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid TumorsBullish
finance.yahoo.com· 2026-06-29
Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid TumorsBullish
finance.yahoo.com· 2026-06-29
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for ImmunotherapyBearish
finance.yahoo.com· 2026-06-26
Tencent Music, CSL among global large caps with persistent bearish Quant signalsBullish
seekingalpha.com· 2026-06-10
OpenFold Consortium Adds Eleven New Members as Momentum Builds for Open AI Infrastructure in Biology and Drug DiscoveryBullish
finance.yahoo.com· 2026-06-09
Assessing Daiichi Sankyo Company (TSE:4568) Valuation After Recent Share Price WeaknessBullish
finance.yahoo.com· 2026-06-03
Can AstraZeneca's Expanding Cancer Portfolio Sustain Momentum?Bullish
finance.yahoo.com· 2026-06-03

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.